

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL

Thomas Chatzikonstantinou,^{1,*} Mariia Mikhaleva,^{2,*} Christian Brieghel,^{3,4} Christina Papangelou,¹ Eva Minga,¹ Celso Arrais-Rodrigues,⁵ Sotiria Besikli-Dimou,¹ Amalia Cerutti,⁶ Michael Doubek,^{7,8} Lisbeth Enggaard,³ Blanca Espinet,⁹ Blanca Ferrer-Lores,¹⁰ Jose Antonio Garcia Vela,¹¹ Massimo Gentile,^{12,13} Eva Gimeno Vázquez,¹⁴ Odit Gutwein,^{15,16} Yair Herishanu,¹⁷ Paula Jablonowska-Babij,¹⁸ Ozren Jaksic,¹⁹ Par Josefsson,³ Elzbieta Kalicińska,¹⁸ Maria Kislova,²⁰ Enrico Lista,²¹ Ioannis Kotsianidis,²² Juan Marquet,²³ Enrica Antonia Martino,¹³ Ciaran McAuley,²⁴⁻²⁶ Maria José Mela Osorio,²⁷ Riccardo Moia,²⁸ Claudia Mosquera,¹² Eugene Nikitin,²⁰ Miguel Arturo Pavlovsky,²⁷ Verena Pfister,⁵ Emine Merve Savaş,²⁹ Lydia Scarfò,^{30,31} Matjaz Sever,³² Lev Shvidel,³³ Martin Simkovic,³⁴ Niki Stavroyianni,³⁵ Persefoni Talimtzis,¹ Antigoni Tranidou,¹ Andrea Visentin,³⁶ Georgios Vrachiolias,²² Ewa Wasik-Szczepanek,³⁷ Tomasz Wróbel,¹⁸ Münci Yağcı,²⁹ Alessandro Cellini,³⁶ Anastasia Chatzidimitriou,¹ Gianluca Gaidano,²⁸ Mary Ann Anderson,^{24,38,39} Matthew S. Davids,² Jennifer R. Brown,² Carsten U. Niemann,^{3,4} Kostas Stamatopoulos,¹ Paolo Ghia,^{30,31} Inhye E. Ahn,^{2,†} and Maya Koren-Michowitz^{15,16,†}

¹Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ³Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; ⁴Hematology Branch, Danish Cancer Institute, Copenhagen, Denmark; ⁵Universidade Federal de Sao Paulo, Sao Paulo, Brazil; ⁶Sanatorio Británico de Rosario, Santa Fé, Argentina; ⁷Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University, Brno, Czech Republic; ⁸Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; ⁹Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar and Translational Research on Hematological Neoplasms Group, Hospital del Mar Research Institute, Barcelona, Spain; ¹⁰Department of Hematology, Hospital Clínico Universitario, Valencia, Spain; ¹¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ¹²Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera di Cosenza, Cosenza, Italy; ¹³Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy; ¹⁴Department of Hematology, Hospital del Mar, Barcelona, Spain; ¹⁵Department of Hematology, Shamir Medical Center, Zerifin, Israel; ¹⁶Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ¹⁷Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ¹⁸Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wrocław Medical University, Wrocław, Poland; ¹⁹Division of Hematology, Department of Medicine, University Hospital Dubrava, Medical School University of Zagreb, Zagreb, Croatia; ²⁰Department of Hematology, Oncology, and Chemotherapy, S. P. Botkin's City Hospital, Moscow, Russian Federation; ²¹Department of Hematology, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari Trento, Trento, Italy; ²²Department of Hematology, Democritus University of Thrace, Alexandroupolis, Greece; ²³Hematology Department, Ramón y Cajal University Hospital, Madrid, Spain; ²⁴Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia; ²⁵Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ²⁶Department of Diagnostic Haematology, Royal Melbourne Hospital, Melbourne, VIC, Australia; ²⁷Fundaleu, Buenos Aires, Argentina; ²⁸Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy; ²⁹Department of Hematology, Gazi University Faculty of Medicine, Ankara, Turkey; ³⁰Università Vita-Salute San Raffaele, Milan, Italy; ³¹Ospedale San Raffaele, Milan, Italy; ³²University Medical Centre, Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ³³Institute of Hematology, Kaplan Medical Center, Rehovot, Israel; ³⁴4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Králové, Czech Republic; ³⁵Hematology Department, Papanicolaou Hospital, Thessaloniki, Greece; ³⁶Hematology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy; ³⁷Department of Hematooncology and Bone Marrow Transplantation, Medical University in Lublin, Lublin, Poland; ³⁸Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute, Melbourne, VIC, Australia; and ³⁹Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia

Submitted 14 July 2025; accepted 23 August 2025; prepublished online on *Blood Advances* First Edition 24 October 2025; final version published online 16 January 2026. <https://doi.org/10.1182/bloodadvances.2025017755>.

*T.C. and M.M. contributed equally to this study.

†I.E.A. and M.K.-M. contributed equally to this study.

Original data are available from the author, Thomas Chatzikonstantinou (thomas.chatzikonstantinou@certh.gr).

The full-text version of this article contains a data supplement.

© 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Key Points

- CLL-CNSi is a rare condition that can affect treatment-naïve patients.
- Initial treatment with BTKi-based therapy is highly effective.

Central nervous system involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare condition with no consensus on diagnostic criteria and limited evidence for management and outcome. Here, we report an international, multicenter, retrospective study conducted by the European Research Initiative on CLL. The study defined CNSi of CLL by the following: (1) detection of CLL cells in the cerebrospinal fluid or confirmation of CLL infiltration of the CNS based on a tissue biopsy, (2) clinical or radiographic evidence of neurologic disease, and (3) the absence of other explanations for the neurologic findings. A total of 48 patients from 26 centers in 15 countries met all 3 diagnostic criteria of CLL-CNSi. Median age at diagnosis of CNSi was 64 years. Most patients were males (73%), had Binet stage A at CLL diagnosis (61%), and had untreated CLL at the time of CNSi (63%). Motor impairment was the most common symptom (38%) followed by visual impairment (32%). Of 47 patients who received treatment for CNSi, half (51%) received targeted agents, most often a Bruton tyrosine kinase inhibitor (BTKi), and 34% received chemoimmunotherapy. Initial treatment was highly effective, leading to a reduction (83%) or complete resolution (71%) of neurologic symptoms and imaging findings in most patients. The estimated 5-year overall survival (OS) from the CNSi diagnosis was 77.1%. The 5-year time to next treatment or death was 94% for patients treated with BTKi compared with 64% for those treated with CIT. Treatment-sensitive disease, represented by attainment of CNS complete response after initial therapy, was associated with longer OS.

Introduction

Central nervous system involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare occurrence with an estimated prevalence of 0.4% to 1.5%.^{1,2} Although the presence of CLL cells in the CNS has been described in autopsy studies,^{3,4} there is a paucity of data on how CLL-CNSi clinically presents and what the outcome is, with previous studies limited to case reports⁴⁻⁴⁴ and small case series.^{1,2,45} Among various neurologic findings reported from other studies, parenchymal brain and leptomeninges were usually involved,^{2,45} and cranial nerve palsies, especially those associated with ophthalmologic manifestations, are common symptoms at presentation.²⁶

Owing to the lack of consensus diagnostic criteria for CLL-CNSi and a wide range of differential diagnoses for patients presenting with neurologic symptoms, the diagnosis of CLL-CNSi is often delayed, and likely missed, with 1 study reporting a median delay of 6 months from the onset of symptoms (range, 1-90).⁴⁵ In previous studies, treatment of CLL-CNSi consisted of chemoimmunotherapy (CIT) given as systemic and/or intrathecal (IT) therapy using either CLL or CNS lymphoma-directed regimens. There has been a lack of data on the safety and efficacy of targeted therapies for CLL-CNSi. To address these knowledge gaps in CLL-CNSi, we conducted an international multicenter retrospective study to assess the clinical characteristics, treatments, and outcome of patients with CLL-CNSi, in particular in the era of targeted therapies.

Methods

Data collection

This is an international, multicenter, retrospective study conducted by the European Research Initiative on CLL, including Dana-Farber

Cancer Institute in the United States as a collaborating institution. Investigators from participating sites contributed deidentified data from consenting patients, who agreed to participate in institutional data collection studies approved by respective institutional ethics committees and conducted according to the Declaration of Helsinki. Danish data collection was approved by the national health authorities. According to Danish legislation, registry studies do not require written informed consent.

We included patients who were diagnosed with CLL or small lymphocytic lymphoma (SLL) and met all 3 of the following diagnostic criteria for CLL-CNSi: (1) detection of CLL cells (by flow cytometry) in the cerebrospinal fluid (CSF) or CNS based on a tissue biopsy, (2) clinical or radiographic evidence of neurologic disease, and (3) the absence of other explanations for the neurologic findings. Patients with red blood cell (RBC) contamination of the CSF and patients with Richter's transformation (RT) at the time of CNSi were excluded. Patients who did not receive treatment for the CLL-CNSi at the time of data cutoff were excluded from the subgroup analyses for the treatments and outcomes. Excluded cases (n = 11) without meeting all 3 diagnostic criteria of CLL-CNSi are summarized in the supplemental Material.

Collected data included baseline demographics; dates of CLL diagnosis and CNSi diagnosis; key prognostic markers of the CLL, including immunoglobulin heavy variable (IGHV) gene somatic hypermutation status, fluorescence in situ hybridization (FISH), *TP53* mutation status assessed by Sanger or next-generation sequencing, lactate dehydrogenase, and beta-2 microglobulin (B2M); symptoms of CNSi; CSF and imaging data collected during the diagnostic workup for the CLL-CNSi; types of CLL- and CNSi-directed treatments; response to CNSi treatment; dates of last follow-up; and survival status. We defined complete remission (CR) of CNS disease by resolution of clinical symptoms with

normalization of CSF and neuroimaging findings. Partial response (PR) was defined by improvement of clinical symptoms with normalization of CSF and at least a 50% decrease of involved sites in neuroimaging. For the CLL-CNSi prevalence calculation, we restricted the analysis to data from the Danish Lymphoid Cancer Research (DALY-CARE) data resource.⁴⁶ Danish cases were identified among patients with CLL and SLL from East Denmark by searching the electronic health record (EHR) for “CLL” and “CNS” within the same sentence. Next, manual EHR review confirmed CLL-CNSi.

Statistical analysis

For descriptive statistics, categorical variables were summarized using frequencies and relative frequencies, whereas median and interquartile range (IQR) were used for the numerical variables. Depending on the context, overall survival (OS) was defined as the time from (1) CLL diagnosis or (2) CNSi diagnosis or (3) CNS-directed treatment to death (event) or the last follow-up date (censoring). Time to next treatment or death (TTNT-D) was defined as the time from the start of the first CNS-directed treatment to initiating the next line of therapy or death (events) or the last follow-up date (censoring), whichever came first.

Both univariable and multivariable Cox regression analyses were conducted using OS as an outcome. Risk factors with a *P* value < .2 in the univariable analyses were included in the multivariable analysis. We performed a stepwise variable selection using Akaike information criterion for the Cox regression. The significance level was set to 5%, and Wald confidence intervals (CIs) were constructed. All statistical analyses were conducted in R (version 4.1.1) using the “survival” package for the Cox regression and the “survminer” package for Kaplan-Meier visualization.

Results

Patient characteristics

We identified 48 patients diagnosed with CLL-CNSi between 2007 and 2024 from 26 centers in 15 countries (supplemental Table 1, Figure 1 for the CONSORT diagram) and meeting the 3 criteria as defined in the Methods section, after excluding 11 additional cases did not meet all criteria, described separately later in the text (supplementary Material). The median age at CLL diagnosis and CNSi diagnosis was 63 (IQR, 53-69) and 64 (IQR, 60-75) years, respectively (Table 1) with a median time from CLL/SLL diagnosis to CNSi of 45.3 months (IQR, 1-103). Most patients were male (35/48, 72.9%) and had Binet stage A at CLL diagnosis (23/38, 60.5%). Although most patients had CLL (40/48, 83.3%), 6 (12.5%) had SLL and 2 (4.2%) had high-count CLL-like monoclonal B-cell lymphocytosis (MBL) before the diagnosis of CNSi. The median follow-up after the CNSi diagnosis was 5.3 years (IQR, 1.8-12.9).

At the time of CNSi, motor impairment was the most common symptom (18/47, 38.3%), followed by visual impairment (15/47, 31.9%), headache (13/47, 27.7%), mental status changes (12/47, 25.5%), and sensory impairment (12/47, 25.5%; supplemental Table 2). The median number of CNSi symptoms at diagnosis was 3 per patient (IQR, 2.3-5). All patients underwent neuroimaging as part of diagnostic workups for the CLL-CNSi. Most patients (38/48, 79.2%) had abnormal radiographic




Figure 1. CONSORT diagram.

findings, most often presenting as a space-occupying lesion (16/48, 33.3%). Other findings included non-space-occupying brain lesions (10/48, 20.8%), leptomeningeal disease (8/48, 16.6%), and cranial nerve infiltration (4/48, 8.3%). Most patients (30/48, 62.5%) were diagnosed with CNSi through confirmation of CLL cells by flow cytometry of the CSF (supplemental Table 2). Furthermore, 11 patients (22.9%) were diagnosed based on CNS biopsy. The remaining 7 patients (14.6%) had both CLL cells in the CSF and a positive CNS biopsy result for CLL involvement.

The status of CLL biomarkers at the time of CNSi diagnosis is summarized in Table 2. Most patients (22/29, 75.9%) had unmutated IGHV genes, an unfavorable prognostic marker. Enrichment of other high-risk markers of CLL was not observed. Trisomy 12 was the most frequently found FISH category (13/33, 39.4%), followed by deletion 13q (11/34, 32.4%). Deletion of 17p and *TP53* mutations were relatively uncommon (7/38 and 2/28 patients, respectively). Complex karyotype with 3 or more chromosomal abnormalities (excluding 1 case with trisomies of chromosomes 12, 18, and 19)⁴⁷ was found in 4 (20%) of 20 evaluable patients (3/4 without concurrent *TP53* aberrations). Elevated lactate dehydrogenase and B2M were observed in approximately half of the evaluable patients (15/27 [55.5%] and 9/17 [52.9%], respectively). Most patients (30/48, 62.5%) were untreated for CLL at the time of CNSi. In addition, 8 patients (16.6%) had previously received 1 line of treatment and 10 (20.8%) received 2 or more lines of therapy for CLL before CNSi diagnosis.

CLL-CNSi prevalence

The prevalence of CNSi was derived from the DALY-CARE resource.⁴⁶ Overall, 4421 patients had medical notes from

Table 1. Patient characteristics

Patient characteristics	No. of patients with the variable/No. of evaluable patients (%)
Sex assigned at birth, n/N with available data (%)	
Female	13/48 (27.1)
Male	35/48 (72.9)
Diagnosis, n/N with available data (%)	
CLL	40/48 (83.3)
SLL	6/48 (12.5)
MBL	2/48 (4.2)
Age at CLL or MBL diagnosis, median (IQR), y	63 (53-69)
Binet stage at CLL diagnosis	
N missing data (% of all patients)	10 (20.8)
A, n/N with available data (%)	23/38 (60.5)
B, n/N with available data (%)	6/38 (15.8)
C, n/N with available data (%)	9/38 (23.7)
Age at CNSi, median (IQR), y	64 (60-75)
Binet stage at CNSi diagnosis	
N missing data (% of all patients)	14 (29.2)
A, n/N with available data (%)	15/34 (44.1)
B, n/N with available data (%)	7/34 (20.6)
C, n/N with available data (%)	12/34 (35.3)
Time (months) from CLL diagnosis to CNSi, median (IQR)	45.3 (1-103)
Total lines of treatment before CNSi, median (IQR)	
0, n/N with available data (%)	30/48 (62.5)
1, n/N with available data (%)	8/48 (16.6)
2-3, n/N with available data (%)	7/48 (14.6)
≥ 4, n/N with available data (%)	3/48 (6.3)
Follow-up time (years) from CLL/SLL diagnosis, median (IQR)	9.2 (3.9-11.8)
Follow-up time (years) from CNSi, median (IQR)	5.3 (1.8-12.9)
Survival status at last follow up, n/N with available data (%)	
Dead	14/48 (29.2)
Alive	34/48 (70.8)
Cause of death, n/N with available data (%)	
CNSi	6/14 (42.9)
Infection	5/14 (35.7)
Other (non CLL related)	2/14 (14.3)
CLL progression	1/14 (7.1)

hematologists in the EHRs of the registry. Seven patients were documented to be treated for CLL-CNSi, whereas 6 met the predefined diagnostic criteria for CLL-CNSi. Thus, the estimated population-based prevalence of confirmed CLL-CNSi in Denmark was 0.14% (6/4421).

CNSi-directed treatment and response

Of 48 patients in our cohort, 47 received CNSi-directed treatment (Table 3). One patient was scheduled to receive ibrutinib monotherapy for the CLL-CNSi but had not yet started treatment at the

time of data cutoff; this case was excluded from subsequent analyses on treatment outcome.

More than 80% of patients received single line of CNSi-directed treatment (38/47, 80.9%). Smaller proportions of patients received 2 (6/47, 12.7%) to 3 or more lines of treatment (3/47, 6.4%). IT chemotherapy was administered in 20 patients (42.6%), and 3 (6.4%) proceeded to allogeneic stem cell transplantation. In the first-line setting, Bruton tyrosine kinase inhibitors (BTKis) given as monotherapy or in combination with an anti-CD20 antibody were most frequently used (18/47, 38.3%; ibrutinib, acalabrutinib, and zanubrutinib in 12, 4, and 2 cases, respectively), followed by fludarabine, cyclophosphamide, and rituximab (FCR; 7/47, 14.9%), venetoclax plus anti-CD20 antibody (4/47, 8.5%), and other CIT regimens typically used in CNS lymphoma (4/47, 8.5%). In the second-line setting, BTKi-based treatment with ibrutinib (3/9, 33.3%) and CNS lymphoma regimens (3/9, 33.3%) were most often used.

Among patients with response data available, rates of overall response (ORR) and CR for the CNS disease to any CNSi-directed treatment were 82.9% (34/41) and 70.7% (29/41), respectively (Table 3). Patients treated with BTKis (monotherapy or in combination with other treatment modalities) had the highest ORR (17/17, 100%) and CR rate (all BTKis: 15/17, 88.2%; ibrutinib: 12/12, 100%; acalabrutinib: 3/4, 75%; zanubrutinib: 1/2, 50%), followed by CIT (ORR: 9/11, 81.8%; CR rate: 8/11, 72.7%) and CNS lymphoma protocols (ORR: 2/3, 66.7%; CR rate: 2/3, 66.7%).

OS and time to next treatment

At the time of data cutoff, 14 patients (29.2%) died. CNSi was the most common cause of death (6/14, 42.9%), followed by infection (5/14, 35.7%). The median OS from CLL diagnosis was 13 years (95% CI 11.1-not estimable [NE]) (supplemental Figure 1), although the median OS from CNSi diagnosis was not reached (95% CI 7.5-NE; Figure 2). The estimated 5-year OS from the CNSi diagnosis was 77.1% (95% CI 64.7%-91.9%). The median TTNT-D from the first CNSi-directed treatment was 11.9 years (95% CI 7.5-NE).

Patients who achieved a CR had better TTNT-D and OS (median not reached for both TTNT-D and OS, supplemental Figure 2 and Figure 2B) than those without a CR (median TTNT-D 3.8 months, median OS 14.5 months). Patients who received CNSi-directed treatment as their first ever treatment for CLL (treatment-naïve CNSi) had a more favorable outcome than those who had been previously treated for CLL and presented with CNSi (relapsed/refractory CNSi). Median TTNT-D and OS were not reached for the treatment-naïve CNSi and were 23 and 100 months, respectively, for the relapsed/refractory CNSi (supplemental Figures 3 and 4). Finally, patients treated with BTKis as part of CNSi therapy had a longer TTNT-D compared with those treated with CIT, including CNS lymphoma regimens (5-year TTNT-D 94.1% [95% CI, = 83.6%-100%] vs 64.2% [95% CI, = 28.7%-100%]); OS did not differ statistically between the 2 groups (5-year OS 94.1% vs 75%, respectively; Figure 3).

We also performed a univariable analysis to identify risk factors associated with inferior OS in patients with confirmed CNSi. Owing to the small sample size and missing information, we focused on 5 variables as found in Figure 4. Older age, not achieving CR after the first CNS-directed treatment, and the number of treatment lines for CLL before CNS-directed treatments

Table 2. Prognostic markers of CLL at diagnosis of CNSi

Prognostic markers	No. of patients with the variable/No. of evaluable patients (%)	Missing	%
IGHV gene status		19	39.6
Mutated	7/29 (24.1)		
Unmutated*	22/29 (75.9)		
FISH hierarchical category			
del(13q)	11/34 (32.4)	14	29.2
del(11q)	8/36 (22.2)	12	25
Trisomy 12	13/33 (39.4)	15	31.3
del(17p)	7/38 (18.4)	10	20.8
<i>TP53</i> mutation status, mutated	2/28 (7.1)	20	41.7
<i>TP53</i> aberration†, present	8/30 (26.7)	18	37.5
<i>NOTCH1</i> mutation status, mutated	2/5 (40)	43	89.6
Karyotype		28	58.3
Normal	7/20 (35)		
1-2 chromosomal abnormalities	8/20 (40)		
3-4 chromosomal abnormalities	3/20 (15)		
5 chromosomal abnormalities	1/20 (5)		
Trisomy (+12, +18, +19)	1/20 (5)		
LDH, above ULN	15/27 (55.5)	21	43.8
Beta-2 microglobulin		31	64.6
≥3.5 mg/L	9/17 (52.9)		
Median (IQR)	3.76 (2.3-5.4)		

LDH, lactate dehydrogenase, ULN, upper limit of normal.

*Unmutated: ≥98% germline identity.

†*TP53* aberration refers to the presence of *TP53* mutation and/or del(17p).

were associated with worse OS in the univariable analysis. In the multivariable analysis, age and the CR status after the first CNS-directed treatment correlated with OS, although only age reached statistical significance.

Patients with unconfirmed CLL-CNSi

We excluded 11 patients from the cohort of CLL-CNSi due to not meeting the predefined diagnostic criteria. Given that these patients had strong clinical suspicion of CLL-CNSi, we separately analyzed their characteristics and outcome (supplemental Tables 4-6). The median age of this group at CLL/SLL and CNSi diagnosis was 64 (IQR 59-70) and 68 (IQR 59-71) years, respectively. All except 1 patient were treated for CNSi, including 4 patients (40%) who received BTKis as their first CNS-directed treatment and 2 patients who received CNS lymphoma regimens. All patients responded to BTKis by achieving at least partial response, and 3 of 4 (75%) achieved CR. Median TTNT-D and median OS from the first CNSi-directed treatment were 5.4 years (95% CI, 0.3-NE) and 9.5 years (95% CI, 1.6-NE), respectively.

Discussion

To our knowledge, this report represents the largest series of patients with CLL-CNSi, including those who received treatment with BTKis. Acknowledging the diagnostic challenges associated

with CLL-CNSi, our study applied a stringent and consistent set of diagnostic criteria for CLL-CNSi by excluding patients without CSF or tissue evidence of CLL and those with RBC contamination of diagnostic CSF samples. In contrast to previous studies,^{1,2} we reported a significantly lower prevalence of CLL-CNSi based on the Danish CLL registry (0.14%). The higher prevalence reported in previous studies might have reflected selection bias created by referral of complex cases to tertiary care centers. The use of population-based data has the advantage of reducing such bias.

In this study, 63% of patients with CLL-CNSi were treatment naive at the time of diagnosis, a rate similar to the report by Wanquet et al⁴⁵ (67% of 30 patients) and higher than that of Strati et al¹ (48% of 18 patients). Two patients in our cohort had MBL at the time of CNSi, which had not been previously reported. These findings indicate that CNSi can occur at any stage or burden of CLL or MBL, suggesting the existence of specific biological features leading to neurotropism rather than an association with advanced disease. Most patients in our cohort carried unmutated IGHV genes (75.9%). Other high-risk features, such as *TP53* aberration (24.1%) and complex karyotype (20.0%), were slightly more frequently observed in our cohort than expected, most of whom had 0 to 1 prior line of therapy. Similarly, trisomy 12 was the most frequently found hierarchical FISH aberration (39.4%), which was more frequent than expected.

Table 3. Treatment for CNSi (N = 47)

Treatment detail	n (%)	Missing	%
Total lines of treatment, Median (IQR)	1 (1-2)	0	0
Total lines of treatment		0	0
1	38 (80.9)		
2	6 (12.7)		
3	2 (4.3)		
4	1 (2.1)		
Intrathecal chemotherapy (IT)	20 (42.6)	0	0
Types of IT		2	10
MTX plus cytarabine plus corticosteroids	8 (44.5)		
MTX	6 (33.3)		
Cytarabine	2 (11)		
MTX plus corticosteroids	1 (5.6)		
MTX plus cytarabine	1 (5.6)		
Allo-SCT	3 (6.4)	0	0
CAR-T therapy	0	0	0
First-line treatment excluding IT therapy*		0	0
Ibrutinib ± anti-CD20 antibody†	11 (23.4)		
FCR	7 (14.9)		
Venetoclax plus anti-CD20 antibody	4 (8.5)		
CNS lymphoma regimen‡	4 (8.5)		
Acalabrutinib ± anti-CD20 antibody	4 (8.5)		
Other CIT	3 (6.3)		
Corticosteroids monotherapy	3 (6.3)		
Zanubrutinib monotherapy	2 (4.3)		
BR	2 (4.3)		
Radiotherapy	2 (4.3)		
Venetoclax monotherapy	2 (4.3)		
Rituximab monotherapy	1 (2.1)		
Ibrutinib plus venetoclax	1 (2.1)		
Cytarabine with corticosteroids	1 (2.1)		
Second-line treatment excluding IT therapy (n = 9)		0	0
CNS lymphoma regimen	3 (33.3)		
Ibrutinib ± anti-CD20 antibody§,	3 (33.3)		
Radiotherapy	1 (11.1)		
Venetoclax plus anti-CD20 antibody	1 (11.1)		
Methotrexate monotherapy	1 (11.1)		
Third-line treatment excluding IT therapy (n = 2)		0	0
Ibrutinib ± anti-CD20 antibody	1 (50)		
CNS lymphoma regimen	1 (50)		
Fourth-line treatment excluding IT therapy (n = 1)			
Venetoclax monotherapy	1 (100)	0	0

Allo-SCT, allogeneic stem cell transplant; BR, bendamustine and rituximab; CAR-T, CD19 chimeric antigen receptor T-cell; FCR, fludarabine, cyclophosphamide, and rituximab.

*All combination partners of BTKis are listed in the "First-line treatment excluding IT therapy" (4/17 cases treated with BTKis received IT also).

†One patient received radiotherapy and corticosteroids in combination with ibrutinib, another patient received ibrutinib plus rituximab, and 9 of 11 received ibrutinib monotherapy.

‡Three patients received protocols containing rituximab, high-dose methotrexate, and cytarabine. One patient received methotrexate, cytarabine, thiotepa, and rituximab (MATRIX).

§One case also received high-dose methotrexate.

||An additional patient received ibrutinib as maintenance after achieving CR.

Table 3 (continued)

Treatment detail	n (%)	Missing	%
CNS response to first-line treatment, ORR n/N evaluable (%); CR n/N evaluable (%)			
All types of treatment	34/41 (82.9); 29/41 (70.7)	6	12.2
BTKi monotherapy or combination*	17/17 (100); 15/17 (88.2)	1	5.5
CIT	9/11 (81.8); 8/11 (72.7)	1	8.3
CNS lymphoma regimen	2/3 (66.7); 2/3 (66.7)	1	25
Venetoclax ± anti-CD20 antibody	2/5 (40); 1/5 (20)	1	20

Allo-SCT, allogeneic stem cell transplant; BR, bendamustine and rituximab; CAR-T, CD19 chimeric antigen receptor T-cell; FCR, fludarabine, cyclophosphamide, and rituximab.

*All combination partners of BTKis are listed in the "First-line treatment excluding IT therapy" (4/17 cases treated with BTKis received IT also).

†One patient received radiotherapy and corticosteroids in combination with ibrutinib, another patient received ibrutinib plus rituximab, and 9 of 11 received ibrutinib monotherapy.

‡Three patients received protocols containing rituximab, high-dose methotrexate, and cytarabine. One patient received methotrexate, cytarabine, thiopeta, and rituximab (MATRIX).

§One case also received high-dose methotrexate.

||An additional patient received ibrutinib as maintenance after achieving CR.

We observed high rates of initial responses to any CNSi-directed treatment, often leading to reduction or complete resolution of neurologic symptoms, CLL cells in CSF, and/or radiographic findings. CR to the first CNSi-directed therapy was observed in 70% of the patients, and an additional 13% partially responded to initial therapy. Treatment-sensitive disease, represented by the CR status, predicted a more favorable outcome with significantly prolonged TTNT-D and OS. These findings highlight the importance of eradicating CNS-resident CLL with initial treatment and the high likelihood of relapse for patients with relative insensitivity to initial CNS-directed therapy. Owing to the retrospective multicenter design of the study, a systematic and time-defined assessment of response status was not performed. Thus, a landmark analysis by CR status was not possible, and the present analysis may have created an unintentional bias for responders.

In our cohort, the estimated 5-year OS from the diagnosis of CNSi was 77.1%. This result was comparable to the 64.3% 5-year OS reported by Wanquet et al,⁴⁵ which primarily used

fludarabine-based CIT or ibrutinib for the treatment of CLL-CNSi. As expected, not being in CR after the first CNS-directed treatment, older age, and a higher number of prior lines of CLL treatment were associated with inferior OS in the univariate analysis. In the multivariate analysis, age and CR status were associated with OS, although the associations did not meet statistical significance. Prognostic markers of CLL, such as *TP53* alteration status, were not included in the model due to the limited number of patients with evaluable data.

Several unique features of our cohort distinguish this study from previous ones on CLL-CNSi. First, we used stringent diagnostic criteria for CLL-CNSi with requirements for pathologic (CSF flow cytometry or tissue biopsy) and clinical/radiographic evidence of disease. Second, the median follow-up of this study was >5 years from the diagnosis of CNSi, which was substantially longer than those of previous studies (12-28 months).^{1,45} Third, the frequent use of BTKi-based therapy (36%) and high rates of initial response to the BTKi-based therapy in our cohort (100% responded,




Figure 2. OS of patients with CNSi. (A) OS from the first diagnosis of CNSi of CLL. (B) OS from the first CNS-directed treatment in patient subgroups divided by CR status after the treatment.




Figure 3. TTNT-D and OS of patients treated with BTKi compared to other therapies. (A) TTNT-D from the first CNS-directed treatment of patients who received BTKi-based regimens vs those who received CIT, including CNS lymphoma treatment regimens. (B) OS from the first CNS-directed treatment of patients who received BTKi-based therapy vs those who received CIT.

including 88% in CR) were unique. Previous studies had small numbers of patients treated with targeted agents (0-6 patients), which precluded further evaluation of the comparative efficacy of treatment approaches. Furthermore, we were able to report significantly longer 5-year TTNT-D associated with BTKi-based therapy (94.1%) than with CIT (64.2%, $P = .042$); OS was also numerically longer for the BTKi-treated patients ($P = .11$). The favorable outcome observed with BTKis can be explained by their ability to cross the blood-brain barrier, as demonstrated in preclinical models^{48,49} and CSF samples from BTKi-treated patients.^{48,50} Many prospective and retrospective studies support the efficacy of BTKis for the treatment of primary and secondary CNS lymphoma (ibrutinib,⁵¹ acalabrutinib,⁵² zanubrutinib,⁵³ and tirabrutinib^{54,55}). Venetoclax can also reach effective CSF levels, although its efficacy is less well studied in the setting of CNS disease.^{23,56}

The pathogenesis of CLL-CNSi remains unclear. In an autopsy series of patients with CLL, CLL cells were found in the CNS in a large proportion of patients in addition to normal lymphocytes in the brain parenchyma.⁵⁷ Retention of CLL cells in the CNS

through chemokine-chemokine receptor interaction could hypothetically lead to symptomatic CNS disease. The fact that more than one-third of our cohort had trisomy 12 also raises the possibility of upregulation of integrin and Notch signaling pathways as potential mechanisms of CLL-CNSi. Treatment with ibrutinib can downregulate CCR7 expression on CLL cells,⁵⁸ which could be linked to the high overall response rate (100%) to BTKi-based therapy. This study did not systematically collect data on the status of *NOTCH1* mutations, chemokines, or expression of CD49d or very late antigen-4, which warrant prospective investigation in the future.

We acknowledge several limitations of this study. First, owing to the retrospective nature of our study, pathologic confirmation of CLL cells in CSF or CNS tissue was not available for 11 patients, who were excluded from the main data set of confirmed cases with CLL-CNSi. We, therefore, separately reported the 11 patients with unconfirmed CLL-CNSi to be comprehensive. Second, we did not set a cutoff for the percentage of CLL cells in the CSF, which may have led to the inclusion of cases that mimic CLL-CNSi (5 cases had fewer than 10 cells per μL). Cases with low numbers of CLL




Figure 4. Univariable and multivariable analyses of risk factors associated with OS after the diagnosis of CLL with CNSi.

cells in the CSF and paraneoplastic antibodies have been reported.⁵⁹ We reasoned that the inclusion of patients with low-burden CLL in CSF was acceptable as these patients met other diagnostic criteria for CNSi with symptomatic disease and/or abnormal neuroimaging findings. Third, responses to CNS-directed treatments were based on review of medical records and not on independent review of imaging.

In conclusion, CLL-CNSi is a rare condition that can affect treatment-naïve patients or those with low-burden disease, including MBL. Patients with CNSi who had not previously received CLL-directed therapy had a trend for better outcome upon treatment for CNSi. Initial treatment with BTKi-based therapy was highly effective, leading to a reduction (83%) or complete resolution (71%) of neurologic symptoms and imaging findings in most patients. The 5-year TTNT-D was 94% for patients treated with BTKis compared with 64% for those treated with CIT, including CNS lymphoma regimens. These data reinforce the importance of targeted agents in CLL, including patients presenting with neurologic symptoms.

Acknowledgments

The authors thank the patients and care providers who participated in institutional data collection studies included in this study.

I.E.A. is a recipient of Blood Cancer United Scholar in Clinical Research Award. P.G. and L.S. are supported, in part, by Associazione Italiana per la Ricerca sul Cancro under 5 per Mille 2018 (ID 21198) program (Foà Roberto).

Authorship

Contribution: T.C., M.M., I.E.A., and M.K.-M. designed and coordinated the study, collected data, and wrote the paper; C.P. and P.T. wrote the manuscript and performed the analysis; E.M., A. Chatzidimitriou, K.S., and P.G. contributed to the study design, interpretation, and manuscript editing; and C.B., C.A.-R., S.B.D., A. Cerutti, M.D., L.E., B.E., B.F.L., J.A.G.V., M.G., E.G.V., O.G., Y.H., P.J., O.J., P.J., E.K., M.K., E.L., I.K., J.M., E.A.M., C.M., M.J.M.O., R.M., C.M., E.N., M.A.P., V.P., M.S., L. Shvidel, M. Sever, L. Scarfò, M. Simkovic, N.S., A.T., A.V., G.V., E.W.S., T.W., M.Y., C.A., G.G., M.A.A., M.S.D., J.R.B., and C.U.N. collected data and contributed to interpretation and manuscript editing.

Conflict-of-interest disclosure: T.C. reports honoraria from AbbVie, AstraZeneca, and BeOne. Y.H. reports honoraria from AbbVie, Janssen, Roche, Medison, and Lilly; served on advisory boards for BeOne and Lilly; and reports research support from Janssen. L. Scarfò reports honoraria from AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly, and Merck. M. Simkovic reports honoraria from, served on advisory boards for, and reports travel

support from AbbVie, AstraZeneca, Swixx Biopharma, Eli Lilly, and Johnson & Johnson. A.V. served on advisory boards for AbbVie, AstraZeneca, BeOne Medicines, CSL Behring, Johnson & Johnson, and Takeda; and speakers' bureaus for AbbVie, Johnson & Johnson, and Lilly. G.G. served on advisory boards and served on speakers' bureaus for AbbVie, AstraZeneca, BeOne, Hikma, Incyte, Johnson & Johnson, and Lilly. M.A.A. is an employee of the Walter and Eliza Hall Institute which receives milestone payments in relation to venetoclax to which M.A.A. is entitled to a share; and reports honoraria from AbbVie, AstraZeneca, Janssen, BeOne, Novartis, Roche, Takeda, CSL, and Gilead. J.R.B. has served as a consultant for AbbVie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeOne, Bristol Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, Loxo/Lilly, Magnet Biomedicine, Merck, and Pharmacyclics; reports research funding from BeOne, Gilead, iOncura, Loxo/Lilly, MEI Pharma, Nagoon Therapeutics, and TG Therapeutics; and serves on the data safety monitoring board for Grifols Therapeutics. P.G. reports honoraria from AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Galapagos, Genmab, Johnson & Johnson, Lilly/LoxoOncology, Merck Sharp & Dohme, and Roche; and research funding from AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Lilly/LoxoOncology, and Merck Sharp & Dohme. K.S. reports research support from AbbVie, AstraZeneca, Janssen, Novartis, and Roche; honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Lilly, and Janssen. I.E.A. reports institutional research funding from BeOne and Lilly; served as a consultant or advisory board for AstraZeneca, BeOne, and Lilly; and reports honoraria from Lilly. M.K.M. reports honoraria from Novartis, Bristol Myers Squibb, and Pfizer. The remaining authors declare no competing financial interests.

ORCID profiles: M.M., [0000-0002-2135-2051](https://orcid.org/0000-0002-2135-2051); C.B., [0000-0002-1816-8106](https://orcid.org/0000-0002-1816-8106); C.P., [0009-0004-9759-7348](https://orcid.org/0009-0004-9759-7348); B.E., [0000-0002-4294-8145](https://orcid.org/0000-0002-4294-8145); B.F.-L., [0000-0001-9452-7310](https://orcid.org/0000-0001-9452-7310); J.A.G.V., [0000-0002-0998-0987](https://orcid.org/0000-0002-0998-0987); M.G., [0000-0002-5256-0726](https://orcid.org/0000-0002-5256-0726); O.G., [0000-0003-0204-099X](https://orcid.org/0000-0003-0204-099X); P.J.-B., [0000-0001-6984-2116](https://orcid.org/0000-0001-6984-2116); E.K., [0000-0002-4797-8001](https://orcid.org/0000-0002-4797-8001); M.K., [0000-0002-8794-0120](https://orcid.org/0000-0002-8794-0120); J.M., [0000-0002-8484-1442](https://orcid.org/0000-0002-8484-1442); R.M., [0000-0001-7393-1138](https://orcid.org/0000-0001-7393-1138); E.N., [0000-0002-2490-1263](https://orcid.org/0000-0002-2490-1263); M.A.P., [0000-0003-4561-3153](https://orcid.org/0000-0003-4561-3153); V.P., [0000-0002-2061-1277](https://orcid.org/0000-0002-2061-1277); L.S., [0000-0002-0844-0989](https://orcid.org/0000-0002-0844-0989); M. Sever, [0000-0002-9487-5451](https://orcid.org/0000-0002-9487-5451); M. Simkovic, [0000-0003-0331-5334](https://orcid.org/0000-0003-0331-5334); A.V., [0000-0003-0271-7200](https://orcid.org/0000-0003-0271-7200); A.C., [0000-0003-1094-9992](https://orcid.org/0000-0003-1094-9992); G.G., [0000-0002-4681-0151](https://orcid.org/0000-0002-4681-0151); J.R.B., [0000-0003-2040-4961](https://orcid.org/0000-0003-2040-4961); C.U.N., [0000-0001-9880-5242](https://orcid.org/0000-0001-9880-5242); P.G., [0000-0003-3750-7342](https://orcid.org/0000-0003-3750-7342); I.E.A., [0000-0003-3717-287X](https://orcid.org/0000-0003-3717-287X); M.K.-M., [0000-0002-7223-328X](https://orcid.org/0000-0002-7223-328X).

Correspondence: Paolo Ghia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; email: ghia.paolo@hsr.it; and Inhye E. Ahn, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; email: Inhye_ahn@dfci.harvard.edu.

References

- Strati P, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. *Haematologica*. 2016;101(4):458-465.
- Hanse MC, Van't Veer MB, van Lom K, van den Bent MJ. Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment. *J Neurol*. 2008;255(6):828-830.

3. Jellinger K, Radaszkiewicz T. Involvement of the central nervous system in malignant lymphomas. *Virchows Arch A Pathol Anat Histol*. 1976;370(4):345-362.
4. Bojsen-Møller M, Nielsen JL. CNS involvement in leukaemia. An autopsy study of 100 consecutive patients. *Acta Pathol Microbiol Immunol Scand A*. 1983;91(4):209-216.
5. Witton LA, Menon S, Perera KS. Central nervous system involvement with chronic lymphocytic leukemia. *Can J Neurol Sci*. 2019;46(5):640-641.
6. Cash J, Fehir KM, Pollack MS. Meningeal involvement in early stage chronic lymphocytic leukemia. *Cancer*. 1987;59(4):798-800.
7. Howard RS, Duncombe AS, Owens C, Graham E. Compression of the optic chiasm due to a lymphoreticular malignancy. *Postgrad Med J*. 1987;63(746):1091-1093.
8. Stagg MP, Gumbart CH. Chronic lymphocytic leukemic meningitis as a cause of the syndrome of inappropriate secretion of antidiuretic hormone. *Cancer*. 1987;60(2):191-192.
9. Pohar S, deMetz C, Poppema S, Hugh J. Chronic lymphocytic leukemia with CNS involvement. *J Neurooncol*. 1993;16(1):35-37.
10. Garicochea B, Cliquet MG, Melo N, del Giglio A, Dorhiac-Llacer PE, Chamone DA. Leptomeningeal involvement in chronic lymphocytic leukemia identified by polymerase chain reaction in stored slides: a case report. *Mod Pathol*. 1997;10(5):500-503.
11. Hagberg H, Lannemyr O, Acosta S, Birgegård G, Hagberg H. Successful treatment of syndrome of inappropriate antidiuretic secretion (SIADH) in 2 patients with CNS involvement of chronic lymphocytic leukaemia. *Eur J Haematol*. 1997;58(3):207-208.
12. Lange CP, Brouwer RE, Brooimans R, Vecht Ch J. Leptomeningeal disease in chronic lymphocytic leukemia. *Clin Neurol Neurosurg*. 2007;109(10):896-901.
13. Cohen JB, Cavaliere R, Byrd JC, Andritsos LA. Hearing loss due to infiltration of the tympanic membrane by chronic lymphocytic leukemia. *Case Rep Hematol*. 2012;589718.
14. Moazzam AA, Drappatz J, Kim RY, Kesari S. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. *J Neurooncol*. 2012;106(1):185-200.
15. de Souza SL, Santiago F, Ribeiro-Carvalho MdM, Arnóbio A, Soares AR, Ornellas MH. Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: a case report and review of the literature. *BMC Res Notes*. 2014;7:645.
16. Zhu J, Wu Z, Fan L, Xu W, Li J. Chronic lymphocytic leukemia with central nervous system invasion: one case report and literature review. *Zhonghua Xue Ye Xue Za Zhi*. 2014;35(7):592-595.
17. Khan K, Malik AI, Almarzouqi SJ, et al. Optic neuropathy due to chronic lymphocytic leukemia proven with optic nerve sheath biopsy. *J Neuroophthalmol*. 2016;36(1):61-66.
18. Tam CS, Kimber T, Seymour JF. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. *Br J Haematol*. 2017;176(5):829-831.
19. Mousinho F, Mendes T, Sousa ESP, et al. Treatment sequencing in a chronic lymphocytic leukemia patient with central nervous system involvement. *Case Rep Hematol*. 2018;7817918.
20. Timmers N, de Maar JS, van Kruisdijk RCM, Klein SK. Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature. *Ann Hematol*. 2018;97(9):1627-1632.
21. Naydenov AV, Taylor LP. Leptomeningeal carcinomatosis in chronic lymphocytic leukemia: a case report and review of the literature. *Oncologist*. 2019;24(9):1237-1245.
22. Otani R, Uzuka T, Matsuda H, Higuchi F, Kim P, Ueki K. Brain invasion by chronic lymphocytic leukemia. *Neuropathology*. 2019;39(1):54-57.
23. Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. *Haematologica*. 2019;104(5):e222-e223.
24. Akdogan O, Guven T, Altindal S, Erdal Y, Emre U. An uncommon neurological manifestation of chronic lymphocytic leukemia: Longitudinally extensive transverse myelitis. *Mult Scler Relat Disord*. 2020;37:101455.
25. Peter E, Roux M, Lachenal F. Chronic lymphocytic leukemia with central nervous system infiltration versus CLL-associated auto-immune disease with neurological involvement: A tricky differential diagnosis. *Rev Neurol (Paris)*. 2020;176(1-2):120-123.
26. Delestre F, Blanche P, Bouayed E, et al. Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. *Surv Ophthalmol*. Jan-Feb 2021;66(1):124-131.
27. Bae WH, Yee M, Song L, Canonico MM, Verhoef PA, Shimabukuro KA. Chronic lymphocytic leukemia with leptomeningeal involvement presenting as an acute encephalopathy. *Perm J*. 2022;26(2):126-131.
28. Batayneh O, Lin A, Abu-Jaradeh O, Wu P, Villamar MF, Sharma P. Symptomatic leptomeningeal carcinomatosis: a rare presentation of chronic lymphocytic leukaemia relapse. *BMJ Case Rep*. Jun 8 2022;15(6):e249940.
29. Evans MG, Shestakova A, Haghighi N, et al. Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing. *Leuk Lymphoma*. Oct 2022;63(10):2479-2483.
30. Parker JL, Mays KM, Pratibhu PP, Pick PW, Block DK. Optic perineuritis presenting as the initial manifestation of central nervous system involvement in rai stage 0 chronic lymphocytic leukemia. *J Neuroophthalmol*. 2022;42(1):e187-e191.
31. Soumerai JD, Takvorian RW, Sohani AR, Abramson JS, Ferry JA. Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. *Lancet Haematol*. 2022;9(10):e796.

32. Vicino A, Cochet S, Pistocchi S, et al. A severe case of neuroleukemiosis caused by B cell chronic lymphocytic leukemia, presenting as mononeuritis multiplex. *J Peripher Nerv Syst*. Jun 2023;28(2):266-268.
33. Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M. Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? *Clin Lymphoma Myeloma Leuk*. 2013;13(3):338-341.
34. Cervilla Muñoz E, Demelo Rodríguez P, García A, Menarguez Palanca J, del Toro Cervera J. Brain biopsy in the diagnosis of leptomeningeal involvement in stage I chronic lymphocytic leukemia. *Clin Case Rep*. 2017;5(12):1919-1922.
35. Mihaljevic B, Smiljanic M, Antic D, Kurtovic NK, Balint MT. Chronic lymphocytic leukemia involvement of central nervous system: clinical diversity, diagnostic algorithm and therapeutic challenges. *Ann Indian Acad Neurol*. 2018;21(1):85-87.
36. Gallastegui N, Cassidy DP, Heros DO, Vega F, Schatz JH. Central nervous system involvement by small lymphocytic lymphoma after a myxoma-related embolic event. *Case Rep Hematol*. 2019;2019(1):1825491.
37. Faje A. Chronic lymphocytic leukemia, a rare cause of pituitary stalk thickening. *Clin Case Rep*. 2020;8(7):1319-1320.
38. Maleita D, Serras Pereira R, Hipolito-Fernandes D, Moura-Coelho N, Cunha JP, Tavares Ferreira J. Optic neuropathy due to chronic lymphocytic leukemia: the first manifestation of the disease. *Am J Ophthalmol Case Rep*. 2020/06/01/2020;18:100603.
39. Nakanishi TIT, Ito T, Fujita S, et al. Refractory chronic lymphocytic leukemia with central nervous system involvement: a case report with literature review. *J Blood Med*. 2020;11:487-502.
40. Karbhari N, Lara-Martinez H, Hill J, John M. Venetoclax: a novel therapeutic agent for CLL with CNS involvement. *Case Rep Oncol*. 2022;15(1):345-350.
41. Dewaide R, Saevels K. Treatment strategy in chronic lymphocytic leukemia with symptomatic central nervous system involvement: a case report. *Clin Case Rep*. 2023;11(11):e7965.
42. Liu L, Hadyah S, Park A, et al. Leukemic infiltration of the optic nerve in chronic lymphocytic leukemia: A case report and review of literature. *Leuk Res Rep*. 2023;20:100391.
43. Szczepanek D, Wąsik-Szczepanek E, Szymczyk A, et al. Central nervous involvement by chronic lymphocytic leukaemia. *Neurol Neurochir Pol*. Mar 2018;52(2):228-234.
44. Christoforidou A, Kapsas G, Bezirgiannidou Z, Papamichos S, Kotsianidis I. Successful treatment of chronic lymphocytic leukemia multifocal central nervous system involvement with ibrutinib. *Turk J Haematol*. 2018;35(2):147-149. Kronik Lenfositik Loseminin Multifokal Santral Sinir Sistemi Tutulumunun Ibrutinib ile Basarili Tedavisi.
45. Wanquet A, Birsen R, Bonnet C, et al. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. *Br J Haematol*. 2017;176(1):37-49.
46. Brieghel C, Werling M, Frederiksen CM, et al. The Danish Lymphoid Cancer Research (DALY-CARE) data resource: the basis for developing data-driven hematology. *Clin Epidemiol*. 2025;17:131-145.
47. Baliakas P, Puiggros A, Xochelli A, et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. *Haematologica*. 2016;101(7):e299-e302.
48. Yu H, Kong H, Li C, et al. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. *Transl Cancer Res*. May 2021;10(5):1975-1983.
49. Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. *Cancer Chemother Pharmacol*. Apr 2018;81(4):783-789.
50. Cao HR, Zhu XY, Zhou L, et al. Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study. *Respir Med*. Mar 2021;178:106328.
51. Jaradat JH, Alkhawaldeh IM, Al-Bojoq Y, et al. Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2025;206:104597.
52. Nizamuddin IA, Epperla N, Malacek M-K, et al. Phase I results of acalabrutinib in combination with durvalumab in primary central nervous system lymphoma: safety, efficacy, and central nervous system penetration. *Blood*. 2024;144(suppl 1):985.
53. Qin LY, Geng Y, Mu JF, et al. Central nervous system involvement in chronic lymphocytic leukemia: a case report and review of literature. *J Med Case Rep*. Jul 10 2024;18(1):315.
54. Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. *Blood*. Jan 28 2016;127(4):411-419.
55. Becking AML, van de Mortel JPM, Tomkins O, et al. Zanubrutinib in bing neel syndrome: efficacy and tolerability. *Leukemia*. May 2025;39(5):1260-1264.
56. Jian Y, Han F, Zhu Y, et al. Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients. *Clin Transl Sci*. Sep 2024;17(9):e70006.
57. Berry K, Farias-Itao DS, Grinberg LT, et al. B and T lymphocyte densities remain stable with age in human cortex. *ASN Neuro*. Jan-Dec 2021;13:17590914211018117.
58. Medina-Gil D, Palomo L, Navarro V, et al. Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia. *Haematologica*. Mar 13 2025;110(8):1758-1773.
59. Lilley K, Swayne A, Watson E, et al. 058 ANTI-CASPR2-ANTIBODY associated encephalitis in a 63-year old male with chronic lymphocytic leukaemia. *J Neurol Neurosurg Psychiatry*. 2018;89(6):A24.1-A24.